Research
Cellular
Recent clinical trials have not observed significant effects of n-3 PUFA supplementation on cardiovascular disease (CVD) events.
This suggests that n-3 PUFA supplementation may not be effective for CVD prevention in recent studies.
StrongRefutesmedium confidence
In contrast to earlier trials, recent clinical trials have not observed significant effects of n-3 PUFA supplementation on cardiovascular disease (CVD) events.
Why this rating
Based on the review of recent clinical trials.
Source
ω-3 Fatty acids, atherosclerosis progression and cardiovascular outcomes in recent trials: new pieces in a complex puzzle
Jason Wu et al. · Heart · 2014
DOI 10.1136/heartjnl-2013-305257
cohortCited 47×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Japanese men had a substantially lower incidence of new coronary artery calcification (CAC) compared to US men (rate ratio=0.26, 95%CI=0.09 to 0.73).Strong
- Circulating n-3 PUFA levels were associated with differences in new-onset of coronary artery calcification (CAC) between middle-aged men in Japan and the USA.Strong
Related findings · Cellular
- Athletes aiming to reduce fat mass and preserve FFM should consume protein intakes in the range of ∼1.8-2.7 g kg(-1) d(-1).Strong
- A minimum daily protein intake of ≥1.6 g/kg is necessary to observe significant improvements in muscle mass from whey protein supplementation.Strong
- Most athletes ideally need 1.2 to 2.0 grams/kg of body weight/day of protein, preferably split across 3-4 meals.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →